The document discusses Parkinson's disease, including its causes, symptoms, stages, diagnosis, treatment, and prevention. Some key points:
- Parkinson's is a progressive nervous system disorder caused by loss of dopamine-producing brain cells. Symptoms include tremors, rigidity, and impaired movement.
- It is staged from 1 to 5 based on severity, from mild symptoms on one side of the body to requiring 24/7 care. Diagnosis is based on symptoms and medical history.
- Treatment focuses on managing symptoms through medications like levodopa and carbidopa that aim to replace dopamine. Surgery like deep brain stimulation may also help in severe cases.
- Risk can be reduced through diet high in omega
Module: Pharmacotherapy III
Module Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Postgraduate, Master of Pharmacy in Clinical Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value associated with it.
During my 1st &2nd year of residency period , i used to teach Anatomy and Orthopaedics for foreign undergraduate medical students. At last year i taught Neurology for one batch. so i posted some of my collections for competely educational purpose coz i believe in knowledge ...inseted of deleting these ppts , they may me useful for others so i shared it ....
Module: Pharmacotherapy III
Module Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Postgraduate, Master of Pharmacy in Clinical Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value associated with it.
During my 1st &2nd year of residency period , i used to teach Anatomy and Orthopaedics for foreign undergraduate medical students. At last year i taught Neurology for one batch. so i posted some of my collections for competely educational purpose coz i believe in knowledge ...inseted of deleting these ppts , they may me useful for others so i shared it ....
Parkinson's disease is a progressive nervous system disorder that affects movement. Symptoms start gradually, sometimes starting with a barely noticeable tremor in just one hand. Tremors are common, but the disorder also commonly causes stiffness or slowing of movement.
Parkinson's Disease, SYMPTOMS OF PARKINSONISM, STAGES OF PARKINSONISM, ETIOLOGY OF PARKINSONISM, PATHOPHYSIOLOGY OF PARKINSONISM, TREATMENT OF PARKINSONISM.
Parkinson's disease is a progressive nervous system disorder that affects movement. Symptoms start gradually, sometimes starting with a barely noticeable tremor in just one hand. Tremors are common, but the disorder also commonly causes stiffness or slowing of movement.
Parkinson's Disease, SYMPTOMS OF PARKINSONISM, STAGES OF PARKINSONISM, ETIOLOGY OF PARKINSONISM, PATHOPHYSIOLOGY OF PARKINSONISM, TREATMENT OF PARKINSONISM.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
PARKINSON DISEASE
1. By- Vijaiy. S & Shreedevi. R
RVS COLLEGE OF PHARMACY, SULUR, COIMBATORE,
TAMILNADU.
2. INTRODUCTION
• It is a slowly progressive degenerative disease of nervous system
associated with damage to basal ganglia followed by destruction of
substantia nigra.
• This causes decrease in dopamine level causing parkinsons diseases.
• It was discovered by English physician James Parkinson in 1817.
• It is also called as Parkinsonism/Paralysis agitans.
• It is found to be 14th major cause for death in US.
5. SYMPTOMS
• Mild noticeable tremor in one hand.
• Bradykinesia
• Rigid muscles.
• Poverty of movements-Loss of activties
including blinking,smiling etc.
• Gait
• Emotional changes.
• Dementia.
• And due to stages
6. CAUSES
• Encephalitis
• Cerebral arteriosclerosis
• Drugs - Prolonged use of Antihpertensive drugs (Eg:Reserpine)
• Low levels of dopamine and norepinephrine, a substance that
regulates dopamine, have been linked with Parkinson’s.
7. • Research has identified groups of people who are more likely to develop
the condition. These include:
• Sex: Men are one and a half times more likely to get Parkinson’s than
women.
• Race: Whites are more likely to get Parkinson’s than African Americans
or Asians.
• Age: Parkinson’s usually appears between the ages of 50 and 60. It
only occurs before the age of 40 in 5-10 percent of cases.
• Family history: People who have close family members with
Parkinson’s disease are more likely to develop Parkinson’s disease, too.
• Toxins: Exposure to certain toxins may increase the risk of Parkinson’s
disease.
• Head injury: People who experience head injuries may be more likely
to develop Parkinson’s disease.
9. Stage one of Parkinson’s disease
• The symptoms of PD are mild and only seen on one
side of the body (unilateral involvement), and there is
usually minimal or no functional impairment
• Symptoms at stage one may include tremor, such as
intermittent tremor of one hand, rigidity, or one hand
or leg may feel more clumsy than another, or one side
of the face may be affected, impacting the expression.
• This stage is very difficult to diagnose and a physician
may wait to see if the symptoms get worse over time
before making a formal diagnosis
10. Stage two of Parkinson’s disease
• It is characterized by symptoms on both sides of the body
(bilateral involvement) or at the midline without impairment to
balance.
• Stage two may develop months or years after stage one.
Symptoms of PD in stage two may include the loss of facial
expression on both sides of the face, decreased
blinking, speech abnormalities, soft voice, monotone voice,
fading volume after starting to speak loudly, slurring speech,
stiffness or rigidity of the muscles in the trunk that may result
in neck or back pain, stooped posture, stooped posture, and
general slowness in all activities of daily living.
• Diagnosis may be easy at this stage if the patient has a
tremor.
11. Stage three of Parkinson’s disease
• It is considered mid-stage and is characterized by loss
of balance and slowness of movement.
• Balance is compromised by the inability to make the rapid,
automatic and involuntary adjustments necessary to
prevent falling, and falls are common at this stage.
• All other symptoms of PD are also present at this stage,
and generally diagnosis is not in doubt at stage three.
• Often a physician will diagnose impairments in reflexes at
this stage by standing behind the patient and gently pulling
the shoulders to determine if the patient has trouble
maintaining balance and falls backward (the physician of
course will not let the patient fall).
12. Stage four of Parkinson’s disease
• Patients with stage four PD may be able to walk and
stand unassisted, but they are noticeably
incapacitated. Many use a walker to help them.
• At this stage, the patient is unable to live an
independent life and needs assistance with some
activities of daily living. The necessity for help with
daily living defines this stage. If the patient is still able
to live alone, it is still defined as stage three.
13. Stage five of Parkinson’s disease
• It is characterized by an inability to rise from a chair
or get out of bed without help, they may have a
tendency to fall when standing or turning, and they
may freeze or stumble when walking.
• Around-the-clock assistance is required at this stage
to reduce the risk of falling and help the patient with
all daily activities. At stage five, the patient may also
experience hallucinations or delusions.
14. DIAGNOSIS
• There’s no specific test for diagnosing Parkinson’s.
Diagnosis is made based on health history, a physical and
neurological exam, as well as a review of signs and
symptoms.
• Imaging tests, such as a CAT scan or MRI, may be used to
rule out other conditions. A dopamine transporter
(DAT) scan may also be used. While these tests don’t
confirm Parkinson’s, they can help rule out other
conditions and support the doctor’s diagnosis.
15. MRI & CT SCAN
A. Normal
B. Stage 1
C. Stage 2
D. Stage 3
E. Stage 4
F. Stage 5
16.
17.
18. TREATMENT
• Medications can control the symptoms of Parkinson's diseases.
• Following are the drugs used in the treatment:
• Levodopa-Dopamine precursor.
• Carbidopa-Peripheral decarboxylase inhibitor.
• Bromocriptine-Dopaminergic agonist.
• Selegilne
• Amantadine-Dopamine facilitator.
• Biperiden-Anticholinergics.
19. • Carbidopa +Levodopa (sinmet) is the 1st choice of drug.On
combination with carbidopa many common side effects of
levodopa, such as nausea, vomiting, and irregular heart
rhythms can be prevented.
• Tolcapone and entacapone. When you take levodopa, a
chemical in your body called COMT makes part of the drug
useless. The drugs tolcapone (Tasmar) and entacapone
(Comtan) block COMT, so the brain can use levodopa more
effectively, which eases Parkinson's symptoms.
• Levodopa is said to be "Gold standard treatment".
21. PARKINSON’S SURGERY
• Surgical interventions are reserved for people who don’t respond
to medication, therapy, and lifestyle changes.
• Two primary types of surgery are used to treat Parkinson’s:
1. Deep BrainStimulation
2. Pump- Delivered Therapy
• Deep brain stimulation
• During deep brain stimulation (DBS), surgeons implant electrodes in
specific parts of the brain. A generator connected to the electrodes
sends out pulses to help reduce symptoms.
22. • Pump-delivered therapy
• In January 2015, the U.S. Food and Drug Administration (FDA)
approved a pump-delivered therapy called Duopa.
• The pump delivers a combination of levodopa and carbidopa. In
order to use the pump, your doctor will have to perform a surgical
procedure to place the pump near the small intestine.
24. PARKINSON’S PROGNOSIS
• Complications from Parkinson’s can greatly reduce quality of life and
prognosis. For example, individuals with Parkinson’s can experience
dangerous falls, as well as blood clots in the lungs and legs. These
complications can be fatal.
• Proper treatment improves your prognosis, and it increases life
expectancy.
• It may not be possible to slow the progression of Parkinson’s, but you
can work to overcome the obstacles and complications to have a better
quality of life for as long as possible.
25.
26. PREVENTION AND DIET
• Go Organic (and Local)
• Eat fresh raw vegetables.
• Incorporate Omega-3 Fatty Acids IntoYour Diet.
• Drink green tea.
• Do regular aerobic exercise.
• Intake of sufficient quantity of CoQ10 enzyme can prevent
or slow down the chances of Parkinson's diseases.Avoid
stress.